SynthesisBMC infectious diseases2025
Pregnancy and neonatal outcomes of HIV infection in pregnant women in Iran: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHIV infection is a major public health concern among pregnant women globally. Beyond the risk of mother-to-child transmission, it can lead to serious complications and negative pregnancy and neonatal outcomes. In Iran, there is currently no comprehensive meta-analysis evidence measuring the adverse pregnancy and neonatal complications of HIV infection among pregnant women. The review objective is to provide pregnancy outcomes, the prevention of mother-to-child transmission (PMTCT), and antiviral therapy (ART) of pregnant women infected with HIV in Iran.
methodsThe review systematically searched PubMed, Scopus, ISI, Embase, and also the Iranian national databases up to 25th September 2024. Any records that reported pregnancy and neonatal outcomes among pregnant women in Iran were included in the inclusion criteria. The study outcomes included any pregnancy and neonatal implications related to HIV infection in pregnant women, as well as PMTCT, ART therapy, delivery type, and HIV morbidity in spouse. Meta-analysis was carried out to estimate pooled prevalence with 95% confidence intervals (CIs) for all the study outcomes.
resultsThe study pooled data from 497 pregnant women infected with HIV across seven eligible studies. The majority of participants had no university education, lived in urban areas, and were infected by their spouses. The most frequent adverse pregnancy outcome was abortion. The pooled proportions and 95% CIs for each outcome were: HIV-positive spouses 78% (95% CI: 73–83%), wanted pregnancy 63% (95% CI: 46–80%), ART and/or PMTCT uptake 94% (95% CI: 89–98%), cesarean delivery 88% (95% CI: 77–98%), live birth rate 98% (95% CI: 96–100%), newborns who were HIV positive 1.0% (95% CI: 0.0–1.0%), and newborn prophylaxis 100% (95% CI: 99–100%).
conclusionAlthough most pregnant women with HIV are enrolled in PMTCT programs and adverse pregnancy and neonatal outcomes are rare, longitudinal, population-based studies are still needed to better understand the situation of pregnant women with HIV in Iran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.